What is Commit Biologics?
Founded in 2021, Commit Biologics is a spin-out from Aarhus University, leveraging over three decades of research in complement system biology. The company specializes in antibody development, aiming to create a new class of therapeutics for cancer and autoimmune diseases. Their approach focuses on harnessing expertise in both antibody engineering and complement pathways to address significant unmet medical needs.
How much funding has Commit Biologics raised?
Commit Biologics has raised a total of $22.2M across 1 funding round:
Angel/Seed
$22.2M
Angel/Seed (2025): $22.2M with participation from Novo Holdings and Bioqube Ventures
Key Investors in Commit Biologics
Novo Holdings
Novo Holdings is a Danish investment company wholly owned by the Novo Nordisk Foundation, focusing on life sciences and healthcare investments.
Bioqube Ventures
Bioqube Ventures is a global life sciences investment firm dedicated to transforming scientific discoveries into innovative medicines, with a focus on early-stage therapeutics.
What's next for Commit Biologics?
The major enterprise-level funding and strategic investment indicate Commit Biologics is poised for significant scaling and advancement of its therapeutic pipeline. This capital infusion will likely accelerate preclinical and clinical development, potentially enabling the company to move towards key milestones in its mission to combat cancer and autoimmune disorders. The company's strong academic foundation and focused therapeutic strategy position it for substantial growth in the competitive biotech landscape.
See full Commit Biologics company page
